ArriVent BioPharma, Inc. Common Stock vs. Eli Lilly & Co.
ArriVent BioPharma, Inc. Common Stock and Eli Lilly & Co. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| AVBP | LLY | |
|---|---|---|
| Market Cap | $1.40 billion | $1.02 trillion |
| Revenue (TTM) | — | — |
| Net Income (TTM) | $-163,735,000 | — |
LLY leads on 1 of 1 size & scale factors.
Valuation
| AVBP | LLY | |
|---|---|---|
| Price / Book | 3.83 | — |
AVBP and LLY split the valuation factors evenly.
Profitability
| AVBP | LLY | |
|---|---|---|
| Return on Equity | -44.63% | — |
AVBP and LLY split the profitability factors evenly.
Dividend
| AVBP | LLY | |
|---|---|---|
| Dividend Yield | — | 0.60% |
AVBP and LLY split the dividend factors evenly.
Risk & Sentiment
| AVBP | LLY | |
|---|---|---|
| Short Interest | 0.04% | 1.29% |
AVBP leads on 1 of 1 risk & sentiment factors.
Dig deeper: AVBP overview, AVBP financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.